Flexion Therapeutics

Woburn, United States Founded: 2007 • Age: 19 yrs Acquired By Pacira
Developer of therapies for the treatment of musculoskeletal disorders
Annual revenue $85.6M Latest available
Total funding $62.0M 4 rounds
Employees 692 Tracked headcount
Investors 7 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About Flexion Therapeutics

Flexion Therapeutics is a company based in Woburn (United States) founded in 2007 was acquired by Pacira in October 2021. Flexion Therapeutics has raised $62 million across 4 funding rounds from investors including Pfizer, Pacira and 5AM Ventures. The company has 692 employees as of December 31, 2022. Flexion Therapeutics operates in a competitive market with competitors including Formation Bio, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.

  • Headquarter Woburn, United States
  • Employees 692 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $85.55 M (USD)
    17
    as on Dec 31, 2020
  • Net Profit
    -$113.71 M (USD)
    24
    as on Dec 31, 2020
  • EBITDA
    -$93.02 M (USD)
    32
    as on Dec 31, 2020
  • Total Equity Funding
    $62 M (USD)

    in 4 rounds

  • Latest Funding Round
    $175 M (USD), Post-IPO

    May 01, 2017

  • Investors
    Pfizer

    & 6 more

  • Employee Count
    692

    as on Dec 31, 2022

  • Acquired by
    Pacira

    (Oct 11, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Flexion Therapeutics

Headcount 500-1000
Employee Profiles 274
Board Members and Advisors 10
Employee Profiles
People
Tyler Jones
Area Director Of Sales-west
People
Bryan Darge
Associate Director Market Access & Reimbursement
People
Anthony Migliore
Territory Manager
People
Derek James L.
Territory Account Manager - Iovera

Unlock access to complete

Board Members and Advisors
people
Mark I. Froimson
Director
people
Paul J Hastings
Chairperson Of The Board

Unlock access to complete

Funding Insights of Flexion Therapeutics

Flexion Therapeutics has successfully raised a total of $62M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $175 million completed in May 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Flexion Therapeutics

Flexion Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Pacira and 5AM Ventures.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital fund backed incubator focused on the healthcare startups
Locked Locked Locked
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999.
Locked Locked Locked
Private equity and venture capital fund focused on the healthcare sector
Locked Locked Locked
Premium access

Investor details for Flexion Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Flexion Therapeutics

Investments
Premium access

Investment portfolio details for Flexion Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Flexion Therapeutics

Premium access

Detailed financials for Flexion Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Flexion Therapeutics Comparisons

Flexion Therapeutics Primary company
Description
Developer of therapies for the treatment of musculoskeletal ...
Location
Woburn, United States
Founded Year
2007
Annual Revenue
$85.55 M (USD)
Net Profit
-$113.71 M (USD)
EBITDA
-$93.02 M (USD)
Employees
692
As of 2022
Premium access

Peer comparison for Flexion Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Flexion Therapeutics

Flexion Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
AI-powered drug discovery platform for various diseases
Locked Locked Locked
Develops antibody-based treatments for autoimmune and inflammatory disorders.
Locked Locked Locked
Drug delivery systems for CNS disorders and pain are developed.
Locked Locked Locked
Reformulated injectables for chemotherapy side effects and pain are developed.
Locked Locked Locked
Therapies for pain and addiction treatment are developed.
Premium access

Detailed competitors of Flexion Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Flexion Therapeutics

Premium access

Complete news archive for Flexion Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Flexion Therapeutics

Flexion Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Flexion Therapeutics is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.

Flexion Therapeutics is a funded company, having raised a total of $62M across 4 funding rounds to date.

As of Dec 31, 2022, the latest employee count at Flexion Therapeutics is 692.

Annual revenue of Flexion Therapeutics is $85.55M as on Dec 31, 2020.

Developer of therapies for the treatment of musculoskeletal disorders. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapies. Their lead program, FX006, is an intra-articular sustained-release steroid injectable for patients with moderate to severe osteoarthritis (OA) pain. They also have two additional product candidates FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

Flexion Therapeutics's top competitors include Formation Bio, Cara Therapeutics and PainReform.

Flexion Therapeutics has 7 investors. Key investors include Pfizer, Pacira, 5AM Ventures, Versant Ventures, and Novo Holdings.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available